genentech press releases:Press Releases
Press Releases
PressReleases.Discoverthelatestnewsaboutourcompany,ourproducts,ourpolicies,andourpeople.426Results.Date,Title,Tags ...。其他文章還包含有:「Media」、「NewsFeatures」、「Genentech:PressReleases|Thursday」、「Genentech:PressReleases|Friday」、「Genentech:PressReleases|Monday」、「Genentech:PressReleases|Thursday」、「genentech」、「Genentech」、「Genentech:PressReleases|Monday」
查看更多 離開網站Media
https://www.gene.com
Get access to Genentech information and resources for stories in development. Find recent and archived press releases. All Media; News Features
News Features
https://www.gene.com
Read press releases and learn about our presence at ASH this year. 1 Nov 2013. FDA Approves New Genentech Medicine for Chronic Lymphocytic Leukemia (CLL) Gazyva.
Genentech: Press Releases | Thursday
https://www.gene.com
“We are pleased that the U.S. FDA has approved the Vabysmo PFS for people living with wet AMD, DME and RVO, which are some of the leading causes ...
Genentech: Press Releases | Friday
https://www.gene.com
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new 5-year data confirming the sustained efficacy and ...
Genentech: Press Releases | Monday
https://www.gene.com
D., Genentech's chief medical officer and head of Global Product Development. “This promising inavolisib-based regimen could transform the PI3K ...
Genentech: Press Releases | Thursday
https://www.gene.com
Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove ...
genentech
https://www.prnewswire.com
News from genentech,+inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/ ...
Genentech
https://twitter.com
Genentech: Press Releases | Tuesday, Jul 16, 2024 · From gene.com. 7. 42 ... Genentech: Press Releases | Monday, Jul 8, 2024. From gene.com. 5.
Genentech: Press Releases | Monday
https://www.gene.com
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks.